SarcopeniaNCT04707963
Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Young Adults
A study testing Peanut protein powder and Full body resistance training in people with Sarcopenia, run by Auburn University at 1 site in United States.
Trial summary
This study will evaluate the adaptations in skeletal muscle that occur in response to 10 weeks of weight training with or without peanut protein supplementation in untrained men and women ages 18-30 Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Sarcopenia
- What is being tested?
- Peanut protein powder and Full body resistance training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 56 participants
- Where
- 1 siteUnited States
- Study dates
- 6 Feb 2021to 31 May 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- body mass index (body mass/height squared) less than 35 kg/m2
- resting blood pressure averaging less than 140/90 mmHg (with or without medication)
Who cannot join
- known peanut allergy
- actively participating in resistance training for more than 2 days/week
- any known overt cardiovascular or metabolic disease
- metal implants that will interfere with x-ray procedures
- medically necessary radiation exposure in the last six months (except dental x-ray)
- any medical condition that would contradict participating in an exercise program, giving blood or donating a skeletal muscle biopsy (i.e. blood clotting disorder or taking blood thinners)
- pregnant or trying to become pregnant
Trial locations and contacts
1 site in 1 country.
About this study
This study will evaluate the adaptations in skeletal muscle that occur in response to 10 weeks of weight training with or without peanut protein supplementation in untrained men and women ages 18-30
Read the detailed description
This is a two-phase study using both novel and conventional methods to assess how PP supplementation affects muscle tissue in young adults who engage in resistance training. These two phases will be conducted as part of a 10-week randomized controlled trial in which men and women aged 18-30 years (n=40), will be stratified by gender and randomized to a resistance training intervention (whole body, two days per week) with PP powder (72g daily; n=10 males, n=10 females) provided during the intervention (immediate group, IG) or after the intervention (wait-list control, WLC, n=10 males, n=10 females). The aims of this study are to determine the acute (deuterium oxide tracer) and chronic (peripheral quantitative computed tomography) effects of PP during resistance training on skeletal muscle myofibrillar protein synthesis rates, changes in skeletal muscle size and quality, changes in whole and appendicular body composition (dual energy x-ray absorptiometry), changes in inflammatory markers and the fecal microbiome.
- Conditions
- Sarcopenia
- Being tested
- Peanut protein powder, Full body resistance training
- Keywords
- resistance training, muscle hypertrophy, muscle quality
- Medical subject headings
- Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Peanut protein powderDietary supplement
Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
Full body resistance trainingBehavioural
Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
| Study group | Role | What they receive |
|---|---|---|
| Immediate Intervention Group | Experimental | Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period Receives: Dietary Supplement: Peanut protein powder; Behavioral: Full body resistance training |
| Wait-list Control Group | Active comparator | Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period Receives: Behavioral: Full body resistance training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in acute myofibrillar protein synthesis rates
Change in right leg vastus lateralis myofibrillar protein synthesis rates using the integrated deuterium oxide technique from biopsies immediately before and 24 hours after resistance exercise
Change in right leg vastus lateralis myofibrillar protein synthesis rates using the integrated deuterium oxide technique from biopsies immediately before and 24 hours after resistance exercise
Measured: 24 hours
Change in mid-thigh skeletal muscle area and quality
Peripheral quantitative computed tomography (pQCT) cross-sectional image of mid-right thigh assessed for overall muscle density (mg/cm^3)
Measured: 0-10 weeks
Secondary outcomes (4)
Change in appendicular lean mass
Change in lean mass (kg) of limbs as measured by dual energy x-ray absorptiometry (DXA)
Measured: 0-10 weeks
Change in Type I and II Muscle Fiber Cross-Sectional Area
Muscle biopsy immunofluorescent staining for determination of type I and type II muscle fiber cross sectional area (fCSA) as a cellular determinant of skeletal muscle hypertrophy
Measured: 0-10 weeks
Change in leg extensor isokinetic dynamometry
maximal isokinetic right leg extensions on an isokinetic dynamometer (BioDex)
Measured: 0-10 weeks
Change in fecal microbiome composition
alpha- and beta-diversity of 16S bacterial rDNA
Measured: 0-10 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2021
- Study start6 Feb 2021
- Primary completion31 May 2021
- Study completion31 May 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Intervention group will receive the supplement during the study period and the wait-listed control group will receive the supplement after the study period. Both groups will participate in resistance training during the 10 week period
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 56 participants (actual)
Sponsor and investigators
- Lead sponsor
- Auburn University
- Sponsor type
- University, hospital or other
- Collaborators
- Edward Via College of Osteopathic Medicine-Auburn, The Peanut Institute
- Responsible party
- Principal investigator, Andrew Fruge, Auburn University
- Investigators
- Michael D Roberts, PhD, Principal investigator, Associate Professor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04707963
- Sponsor's protocol ID
- 19-249B
- Status last verified
- Jun 2021
- First submitted
- 10 Jan 2021
- Last updated
- 9 Jun 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Deidentified anthropometric, physiological, biological and performance data may be requested
Publications
Sexton CL, Smith MA, Smith KS, Osburn SC, Godwin JS, Ruple BA, Hendricks AM, Mobley CB, Goodlett MD, Fruge AD, Young KC, Roberts MD. Effects of Peanut Protein Supplementation on Resistance Training Adaptations in Younger Adults. Nutrients. 2021 Nov 9;13(11):3981. doi: 10.3390/nu13113981.
PubMed 34836236
Study at a glance
From the registry record, last updated by the sponsor on 9 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Young Adults
- ClinicalTrials.gov ID
- NCT04707963
- Acronym / sponsor ID
- 19-249B
- Conditions
- Sarcopenia
- Keywords
- resistance training, muscle hypertrophy, muscle quality
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 56 participants (actual)
- Lead sponsor
- Auburn UniversityUniversity, hospital or other
- Collaborators
- Edward Via College of Osteopathic Medicine-Auburn, The Peanut Institute
- Study start
- 6 Feb 2021 (actual)
- Primary completion
- 31 May 2021 (actual)
- Study completion
- 31 May 2021 (actual)
- First posted
- 13 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the adaptations in skeletal muscle that occur in response to 10 weeks of weight training with or without peanut protein supplementation in untrained men and women ages 18-30
Detailed description
This is a two-phase study using both novel and conventional methods to assess how PP supplementation affects muscle tissue in young adults who engage in resistance training. These two phases will be conducted as part of a 10-week randomized controlled trial in which men and women aged 18-30 years (n=40), will be stratified by gender and randomized to a resistance training intervention (whole body, two days per week) with PP powder (72g daily; n=10 males, n=10 females) provided during the intervention (immediate group, IG) or after the intervention (wait-list control, WLC, n=10 males, n=10 females). The aims of this study are to determine the acute (deuterium oxide tracer) and chronic (peripheral quantitative computed tomography) effects of PP during resistance training on skeletal muscle myofibrillar protein synthesis rates, changes in skeletal muscle size and quality, changes in whole and appendicular body composition (dual energy x-ray absorptiometry), changes in inflammatory markers and the fecal microbiome.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Intervention group will receive the supplement during the study period and the wait-listed control group will receive the supplement after the study period. Both groups will participate in resistance training during the 10 week period
| Arm | Type | Receives |
|---|---|---|
| Immediate Intervention Group | Experimental | Dietary Supplement: Peanut protein powder, Behavioral: Full body resistance trainingParticipants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period |
| Wait-list Control Group | Active comparator | Behavioral: Full body resistance trainingParticipants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- body mass index (body mass/height squared) less than 35 kg/m2
- resting blood pressure averaging less than 140/90 mmHg (with or without medication)
Key exclusion criteria (7 listed)
- known peanut allergy
- actively participating in resistance training for more than 2 days/week
- any known overt cardiovascular or metabolic disease
- metal implants that will interfere with x-ray procedures
- medically necessary radiation exposure in the last six months (except dental x-ray)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Peanut protein powderPeanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water | Dietary supplement | Immediate Intervention Group |
| Full body resistance trainingParticipants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set) | Behavioural | Immediate Intervention Group, Wait-list Control Group |
Primary outcome
Change in acute myofibrillar protein synthesis rates
Time frame: 24 hours
Change in right leg vastus lateralis myofibrillar protein synthesis rates using the integrated deuterium oxide technique from biopsies immediately before and 24 hours after resistance exercise Change in right leg vastus lateralis myofibrillar protein synthesis rates using the integrated deuterium oxide technique from biopsies immediately before and 24 hours after resistance exercise
Change in mid-thigh skeletal muscle area and quality
Time frame: 0-10 weeks
Peripheral quantitative computed tomography (pQCT) cross-sectional image of mid-right thigh assessed for overall muscle density (mg/cm^3)
4 secondary outcomes
Change in appendicular lean mass
Time frame: 0-10 weeks
Change in Type I and II Muscle Fiber Cross-Sectional Area
Time frame: 0-10 weeks
Change in leg extensor isokinetic dynamometry
Time frame: 0-10 weeks
Change in fecal microbiome composition
Time frame: 0-10 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jun 2021.
- Derived from this study: PubMed 34836236Sexton CL, Smith MA, Smith KS, Osburn SC, Godwin JS, Ruple BA, Hendricks AM, Mobley CB, Goodlett MD, Fruge AD, Young KC, Roberts MD. Effects of Peanut Protein Supplementation on Resistance Training Adaptations in Younger Adults. Nutrients. 2021 Nov 9;13(11):3981. doi: 10.3390/nu13113981.
- Individual participant dataSharing planned: No. Deidentified anthropometric, physiological, biological and performance data may be requested
Related trials for Sarcopenia
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
MF-300 for Treatment of Age-Related Sarcopenia
Sarcopenia in Elderly
Not yet recruitingObservational study
Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Hypothyroidism, Psychometrics
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael D Roberts, PhD principal investigator
Associate Professor
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Peanut protein powder and Full body resistance training in people with Sarcopenia, run by Auburn University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in acute myofibrillar protein synthesis rates (time frame: 24 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04707963, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2021.